Sinopharm Kunming Plasma-derived Biotherapies Co., Ltd, Kunming, China.
Department of Gynecology and Obstetrics, the First Affiliated Hospital of Kunming Medical University, Kunming, China.
Biomarkers. 2023 Sep;28(6):477-485. doi: 10.1080/1354750X.2023.2198168. Epub 2023 Jul 2.
The soluble programmed death ligand-1 (sPD-L1) and its prognostic role in cancers have been investigated in numerous studies. However, due to the inconsistency on some findings, this meta-analysis was performed to assess the prognostic value of sPD-L1 in patients with cancer.
We searched the PubMed, Web of Science, MEDLINE, Wiley Online Library and ScienceDirect, and screened the studies for eligibility. Recurrence-free survival (RFS), progression-free survival (PFS) and disease-free survival (DFS) were for short term survival. The overall survival (OS) was for long term survival.
Forty studies with 4441 patients were included in this meta-analysis. Elevated sPD-L1 was associated with short OS [HR = 2.44 (2.03-2.94), = 0.000]. Moreover, a high sPD-L1 was predictive of worse DFS/RFS/PFS [HR = 2.52 (1.83-3.44), = 0.000]. In addition, high sPD-L1 was consistently correlated with poor OS in irrespective of study type, univariate and multivariate analysis, ethnicity, cut-off value of sPD-L1, sample and treatment. In the subgroup analysis, high sPD-L1 was correlated with poor OS in gastrointestinal cancer, lung cancer, hepatic cancer, oesophageal cancer and clear cell renal cell carcinoma.
The present meta-analysis showed that a high level of sPD-L1 was associated with worse prognosis in some types of cancer.
可溶性程序性死亡配体-1（sPD-L1）及其在癌症中的预后作用已在众多研究中进行了探讨。然而，由于一些研究结果不一致，因此进行了这项荟萃分析，以评估 sPD-L1 在癌症患者中的预后价值。
我们检索了 PubMed、Web of Science、MEDLINE、Wiley Online Library 和 ScienceDirect，并筛选了符合条件的研究。无复发生存期（RFS）、无进展生存期（PFS）和无病生存期（DFS）用于短期生存。总生存期（OS）用于长期生存。
这项荟萃分析纳入了 40 项研究，共 4441 名患者。sPD-L1 升高与 OS 较短相关[HR=2.44（2.03-2.94），=0.000]。此外，sPD-L1 升高预示着 DFS/RFS/PFS 更差[HR=2.52（1.83-3.44），=0.000]。此外，sPD-L1 升高与 OS 不良在不论研究类型、单因素和多因素分析、种族、sPD-L1 截断值、样本和治疗均一致相关。在亚组分析中，sPD-L1 升高与胃肠道癌、肺癌、肝癌、食管癌和透明细胞肾细胞癌的 OS 不良相关。
本荟萃分析表明，sPD-L1 水平升高与某些类型癌症的预后较差相关。
